Sharekhan's research report on Vinati Organics
Q1 results were weak and reflected volume pressure primarily due to destocking of ATBS inventory and a fall in margin amid a favourable revenue mix and impact on operating leverage. Thus, consolidated PAT of Rs. 83 crore (down 28% q-o-q) was 10% below our estimates. H2FY23 saw high ATBS offtake given supply chain concern which led to overstocking of ATBS with the customers. The company expects normalisation in H2FY24 and ATBS capacity expansion by 20000 TPA would get delayed to Q4FY24 or early next fiscal as compared to earlier commissioning target of Q3FY24. We cut our FY24/FY25 earnings estimate by 18%/15%. Management’s FY24 revenue/margin guidance of Rs. 2,000 crore/28% implies steep earnings de-growth in current fiscal. FY25 revenue growth guidance of 20-25% led by pick-up in antioxidants and recovery in ATBS. Investment of Rs. 280 crore on niche like MEHQ & Guaiacol and Iso Amylene would also get delayed by 6 months to March 2024. Also, VAPL merger is still pending with NCLT.
Outlook
We maintain a Hold rating on Vinati Organics Ltd with a revised PT of Rs. 1,900 given muted earnings outlook amid a challenging environment and rich valuation of 46x/33x its FY2023E/FY2024E EPS limits any meaningful upside from CMP.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.